<DOC>
	<DOCNO>NCT02509065</DOCNO>
	<brief_summary>The current study design determine effect mean glucose , hypoglycemia , glucagon usage , insulin usage adjust upward glucose target bi-hormonal bionic pancreas , determine whether target adequate glycemic control achieve insulin-only bionic pancreas minimal hypoglycemia .</brief_summary>
	<brief_title>The Set-Point Study : Evaluating Effects Changing Glucose Target Bionic Pancreas Performance</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Age ≥ 18 year clinical type 1 diabetes least one year Diabetes manage use insulin pump ≥ 6 month Prescription medication regimen stable &gt; 1 month ( except medication affect safety study expect affect outcome study , judgment principal investigator ) Live within 60 minute drivetime radius central monitoring location Willing remain within 120 minute drivetime radius central monitoring location throughout study Have someone 18 year age live , access sleep , willing house subject sleeping , willing receive call study staff check welfare study subject telemetry show technical problem severe biochemical hypoglycemia without subject response subject answer telephone ( two individual share role , must willing carefully coordinate subject one clearly designated responsibility give time ) Willing wear two infusion set one CGM sensor change set frequently ( least one new glucagon infusion set daily bihormonal arm , insulin infusion set every day throughout study ) Unable provide inform consent ( e.g . impaired cognition judgment ) Unable safely comply study procedure report requirement ( e.g . impairment vision dexterity prevents safe operation bionic pancreas , impaired memory , unable speak read English ) Current participation another diabetesrelated clinical trial , judgment principal investigator , compromise result study safety subject Pregnancy ( positive urine HCG ) , breast feeding , plan become pregnant immediate future , sexually active without use contraception Need go outside designate geographic boundary study Current alcohol abuse ( intake average &gt; 3 drink daily last 30 day ) , use marijuana within 1 month enrollment , substance abuse ( use within last 6 month control substance marijuana without prescription ) Unwilling unable refrain drink 2 drink hour 4 drink day use marijuana trial Unwilling unable avoid use drug may dull sensorium , reduce sensitivity symptom hypoglycemia , hind decision make period participation study ( use beta blocker allow long dose stable subject meet criterion hypoglycemia unawareness take stable dose , use benzodiazepine narcotic , even prescription , may exclude accord judgment principal investigator ) History liver disease expect interfere antihypoglycemia action glucagon ( e.g . liver failure cirrhosis ) . Other liver disease ( i.e . active hepatitis , steatosis , active biliary disease , tumor liver , hemochromatosis , glycogen storage disease ) may exclude subject cause significant compromise liver function may unpredictable fashion . Renal failure dialysis Personal history cystic fibrosis , pancreatitis , pancreatic tumor , pancreatic disease besides type 1 diabetes Any known history coronary artery disease include , limited , history myocardial infarction , stress test showing ischemia , history angina , history intervention coronary artery bypass grafting , percutaneous coronary intervention , enzymatic lysis presume coronary occlusion ) Abnormal EKG consistent coronary artery disease increase risk malignant arrhythmia include , limited , evidence active ischemia , prior myocardial infarction , proximal LAD critical stenosis ( Wellen 's sign ) , prolong QT interval ( &gt; 440 m ) . Nonspecific ST segment T wave change ground exclusion absence symptom history heart disease . A reassuring evaluation cardiologist abnormal EKG finding may allow participation . Congestive heart failure ( establish history CHF , low extremity edema , paroxysmal nocturnal dyspnea , orthopnea ) History TIA stroke Seizure disorder , history nonhypoglycemic seizure within last two year , ongoing treatment anticonvulsant History hypoglycemic seizure ( grandmal ) coma last year History pheochromocytoma : fractionate metanephrines test patient history increase risk catecholamine secrete tumor : oEpisodic treatment refractory ( require 4 medication achieve normotension ) hypertension oParoxysms tachycardia , pallor , headache oPersonal family history MEN 2A , MEN 2B , neurofibromatosis , von HippelLindau disease History adrenal disease tumor Hypertension systolic BP ≥160 mm Hg diastolic BP ≥100 despite treatment Untreated inadequately treat mental illness ( indicator would include symptoms psychosis , hallucination , mania , psychiatric hospitalization last year ) , treatment antipsychotic medication know affect glucose regulation . Electrically powered implant ( e.g . cochlear implant , neurostimulators ) might susceptible RF interference Unable completely avoid acetaminophen duration study History adverse reaction glucagon ( include allergy ) besides nausea vomit Established history allergy severe reaction adhesive tape must use study History eat disorder within last 2 year , anorexia , bulimia , diabulemia omission insulin manipulate weight History intentional , inappropriate administration insulin lead severe hypoglycemia require treatment Use oral ( e.g . thiazolidinediones , biguanides , sulfonylurea , glitinides , DPP4 inhibitor , SGLT2 inhibitor ) antidiabetic medication Lives frequents area poor Verizon wireless network coverage ( would prevent remote monitor ) Any factor , opinion principal investigator would interfere safe completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bionic pancreas</keyword>
	<keyword>artificial pancreas</keyword>
	<keyword>insulin</keyword>
	<keyword>glucagon</keyword>
	<keyword>continuous glucose monitor ( CGM )</keyword>
	<keyword>insulin pump</keyword>
	<keyword>outpatient</keyword>
</DOC>